These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22364166)

  • 1. If roflumilast inhibits the innate immunity in the stable patient, what about infection?
    Blasco LM
    Clin Respir J; 2013 Jan; 7(1):e11-2. PubMed ID: 22364166
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to commentary: 'If roflumilast inhibits the innate immunity in the stable patient, what about infection?'.
    Buenestado A; Grassin-Delyle S; Guitard F; Naline E; Faisy C; Israël-Biet D; Sage E; Bellamy JF; Tenor H; Devillier P
    Clin Respir J; 2013 Jul; 7(3):e20-1. PubMed ID: 23763715
    [No Abstract]   [Full Text] [Related]  

  • 3. Roflumilast (Daliresp) for COPD.
    Med Lett Drugs Ther; 2011 Jul; 53(1369):59-60. PubMed ID: 21778965
    [No Abstract]   [Full Text] [Related]  

  • 4. Roflumilast for severe COPD?
    Drug Ther Bull; 2011 Apr; 49(4):45-8; quiz iii-iv. PubMed ID: 21467576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphous Light Eruptions Treated With Roflumilast 0.3% Cream: A Case Report.
    Garg KS; Kircik L; Tjahjono L
    J Drugs Dermatol; 2024 Aug; 23(8):686-687. PubMed ID: 39093641
    [No Abstract]   [Full Text] [Related]  

  • 6. Roflumilast cream (Zoryve) for atopic dermatitis.
    Med Lett Drugs Ther; 2024 Sep; 66(1711):150-151. PubMed ID: 39250342
    [No Abstract]   [Full Text] [Related]  

  • 7. No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine.
    Böhmer GM; Gleiter CH; Mörike K; Nassr N; Walz A; Lahu G
    J Clin Pharmacol; 2011 Apr; 51(4):594-602. PubMed ID: 20484614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of the advances in chronic obstructive pulmonary disease treatment.
    Metzger NL; Lundquist LM
    J Pharm Pract; 2012 Dec; 25(6):576-82. PubMed ID: 23076966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential role of racecadotril in the treatment of diarrhea associated with roflumilast.
    López-Campos JL; Gutiérrez C; Calero C
    Arch Bronconeumol; 2012 Nov; 48(11):426. PubMed ID: 22560927
    [No Abstract]   [Full Text] [Related]  

  • 10. Roflumilast added to triple therapy in patients with severe COPD: a real life study.
    Muñoz-Esquerre M; Diez-Ferrer M; Montón C; Pomares X; López-Sánchez M; Huertas D; Manresa F; Dorca J; Santos S
    Pulm Pharmacol Ther; 2015 Feb; 30():16-21. PubMed ID: 25445930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of pharmacokinetic interaction between roflumilast and digoxin in healthy adults.
    Eckermann G; Lahu G; Nassr N; Bethke TD
    J Clin Pharmacol; 2012 Feb; 52(2):251-7. PubMed ID: 21257799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies.
    Kelly K; Mejia A; Suhasini AN; Lin AP; Kuhn J; Karnad AB; Weitman S; Aguiar RC
    Clin Cancer Res; 2017 Mar; 23(5):1186-1192. PubMed ID: 27542768
    [No Abstract]   [Full Text] [Related]  

  • 13. Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study.
    Papp KA; Gooderham M; Droege M; Merritt C; Osborne DW; Berk DR; Thurston AW; Smith VH; Welgus H
    J Drugs Dermatol; 2020 Aug; 19(8):734-740. PubMed ID: 32845114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trial of Roflumilast Cream for Chronic Plaque Psoriasis.
    Lebwohl MG; Papp KA; Stein Gold L; Gooderham MJ; Kircik LH; Draelos ZD; Kempers SE; Zirwas M; Smith K; Osborne DW; Trotman ML; Navale L; Merritt C; Berk DR; Welgus H;
    N Engl J Med; 2020 Jul; 383(3):229-239. PubMed ID: 32668113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to roflumilast under dose-escalation strategy in Korean patients with COPD.
    Park TS; Kang J; Lee JS; Oh YM; Lee SD; Lee SW
    Int J Chron Obstruct Pulmon Dis; 2019; 14():871-879. PubMed ID: 31354255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.
    Rogliani P; Calzetta L; Cazzola M; Matera MG
    Expert Opin Drug Saf; 2016 Aug; 15(8):1133-46. PubMed ID: 27279341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study.
    Blokland A; Van Duinen MA; Sambeth A; Heckman PRA; Tsai M; Lahu G; Uz T; Prickaerts J
    Neurobiol Aging; 2019 May; 77():37-43. PubMed ID: 30776650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide.
    Lahu G; Nassr N; Herzog R; Elmlinger M; Ruth P; Hinder M; Huennemeyer A
    J Clin Pharmacol; 2011 Apr; 51(4):586-93. PubMed ID: 20466871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses.
    Vanmierlo T; Creemers P; Akkerman S; van Duinen M; Sambeth A; De Vry J; Uz T; Blokland A; Prickaerts J
    Behav Brain Res; 2016 Apr; 303():26-33. PubMed ID: 26794595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the therapeutic index of a novel phosphodiesterase 4B-selective inhibitor over phosphodiesterase 4D in mice.
    Suzuki O; Mizukami K; Etori M; Sogawa Y; Takagi N; Tsuchida H; Morimoto K; Goto T; Yoshino T; Mikkaichi T; Hirahara K; Nakamura S; Maeda H
    J Pharmacol Sci; 2013; 123(3):219-26. PubMed ID: 24152964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.